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Background. Osteonecrosis of the jaw (ONJ) has been reported to be associated with patients receiving primarily bisphosphonate
(BP) therapies. However, lately it has been documented that other medications, such as RANK ligand inhibitor (denosumab) and
antiangiogenic drug, can cause ONJ. Micro-osseous-vascular reconstruction of the jaws in patients affected by medication-related
osteonecrosis of the jaw represents a viable option of treatment for patients affected by stage III of the disease. However, there
are still considerable doubts about the success of this procedure in the short, medium, and long term. Material and Methods. A
multidatabase (PubMed/MEDLINE, EMBASE, and CENTRAL) systematic search was performed. Any type of studies considering
human patients treated with antiresorptive and antiangiogenic drugs was considered. The aim of the research is to primarily
understand the success rate ofmicro-osseous-vascular reconstruction in the short,medium, and long period of time.This reviewhas
also the goal of better understanding any perioperative and postoperative complications resulting from the use of the reconstruction
techniques. Results. Eighteen studies resulted eligible for the study. Fibula free flap is the most commonly utilised vascularised free
flap reconstruction technique (80.76%). Ten out of eighteen studies reported no complications. Recurrence of osteonecrosis was
registered in five cases (6.41%) after free flap reconstruction.The overall free flap success rate was 96.16%.Conclusions. Based on the
limited data available in literature (Level 4 of the Oxford Evidence-based medicine scale), micro-osseous-vascular reconstruction
of the jaws represents a valid treatment in patients with bisphosphonate-related osteonecrosis at stage III of the disease. However,
additional data based on a larger cohort of patients are necessary to justify this type of intervention in patient affected by MRONJ.
1. Introduction
Bisphosphonates (BP) are antiresorptive drugs used in the
management of conditions as diverse as osteoporosis and
metastatic bone diseases. These drugs are widely adminis-
tered and generallywell tolerated by patients. In 2003,Marx et
al. [1] first reported a nonhealing necrosis of the maxillofacial
region in some patients taking BPs.
In the last decade researchers have discovered that
BPs not exclusively cause osteonecrosis of jaws, as other
drugs, such as antiresorptive (bone-targeted) agents like
denosumab, but also were found to cause it. In addi-
tion, monoclonal antibodies able to bind and selectively
inhibit VEGF-A, specifically mTOR inhibitors, can also cause
osteonecrosis of the jaw [2–6].
For this reason, in 2014 the bisphosphonate-related
osteonecrosis of the jaw (BRONJ) nomenclature was changed
by the position paper of the American Association of Oral
and Maxillofacial Surgeons (AAOMS) special committee on
Medication-Related Osteonecrosis of the Jaws (MRONJ) [7].
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The term “medication-related osteonecrosis of the jaws”
(MRONJ) refers to a complication associated with groups
of medications, such as antiangiogenic or antiresorptive
drugs [8]. These medications can have different indications
depending on their mode of administration (Tables 1 and 2)
[9, 10].
According to AAOMS, MRONJ is defined as an exposi-
tion of necrotic bone in the oral cavity lasting more than 8
weeks, in patients who took antiresorptive or antiangiogenic
drugs; these patients have not been exposed to head and
neck radiotherapy, nor show signs of bone metastases in the
maxillofacial region [7].
A number of systemic risk factors have been associated
with increased likelihood of MRONJ; they are summarised
in Table 3 [11, 12].
Dental extraction or other surgical procedures such as
apicectomies or cystectomies have been found in between
52% and 80% of MRONJ patients’ medical history [13–15].
During the last decade AAOMShas revised and proposed
a clinical staging classification system of the disease in an
attempt to guide clinicians and surgeons to an appropriate
therapeutic approach (Table 4).
The management of MRONJ is reported to be very
challenging and with no current “gold standard”. Published
studies have reported a number of approaches to treatment,
with widely varying success rates, ranging from no or limited
to radical surgery. The ideal outcome is total eradication of
MRONJ alongwith an improvement of patients' quality of life
through pain release and infection management [16].
Conservative treatment was considered to be partially
successful, with resolution reported in only 50% of cases;
particular concerns have been reported onMRONJ at clinical
stages II and III [17–19]. In case conservative treatments fail,
surgical approaches like local debridement, osteoplasty, and
segmental osteotomy are normally performed [20, 21].
However, patients that show evidence of MRONJ stage
III with severe pain, infection, pathologic fracture, extra-oral
fistula, or osteolysis extending to the inferior border of the
mandible require an invasive type of surgery which might
result in a disabling outcome [7, 16, 22].
The absence of a well-established surgical treatment
protocol in scientific literature makes it difficult to conduct
therapy in advanced cases of the disease.
Up to date, there is no standard treatment for MRONJ
associated with antiresorptive and antiangiogenic therapies.
Several treatment options have been described sinceMRONJ
was first reported. Although the initial stages of MRONJ
seem to respond quite well to conservative treatments or
limited bone debridement if conservative treatment fails, the
treatment for stage III lesions remains still controversial [23,
24].
The objective of this review is to evaluate the outcome
of free vascularised osseous tissue transfer and/or osteo-
fasciocutaneous free flap as treatment for patients affected
by MRONJ stage III. Systematic reviews have been already
published. However, these reviews were not performed in a
standardised manner or did not follow strict criteria. More-
over the previous reviews did not consider antiangiogenic
drugs in the search criteria.This has resulted in lack of quality
assurance, summarised in Table 5 [25–27]. This review aims
to improve the quality of previous research and expand on the
current data available.
2. Materials and Methods
This systematic review was performed according to PRISMA
guidelines [44].
The following the databases were used for the review:
PubMed/MEDLINE, EMBASE, andCochraneCentral Regis-
ter of Controlled Trials (CENTRAL). A three-stage screening
approach was used to ensure precision and the quality of
the search. The screening of titles and abstracts was carried
out independently by three authors (AH, UH, and RS)
to eliminate any irrelevant materials (i.e., reviews, animal
studies, nonclinical studies, and studies that did not report on
patients undergoing to free tissue graft). Disagreements were
resolved by discussion.
A data screening and abstraction form was used to
(1) verify the study eligibility derived from the above
inclusion/exclusion criteria,
(2) carry out the methodological quality assessment,
(3) extract data on study characteristics and outcomes for
the included studies.
The authors of any studies eligible for inclusion in the
review, yet without sufficient information, were contacted
directly (Figure 1).
2.1. Criteria for Inclusion in This Review
2.1.1. Types of Studies. The types of studies included in the
research strategy were published or unpublished randomised
control trials, case-controlled trials, case series, retrospective
studies, and case reports. Papers were obtained from January
2003 to June 2017. Animal studies and those including
patients with previous history of radiation therapy to the head
and neck regions were excluded. No language restrictions
were imposed to the search.
2.1.2. Types of Participants. The review considered studies
involving patients who developed MRONJ and subsequently
underwent free vascularised osseous tissue transfer and/or
osteofasciocutaneous free flap reconstruction. No restriction
of age, gender, or ethnic origin was applied. There was no
restriction on the minimum number of patients included in
the studies.
2.1.3. Types of Interventions. Only free vascularised osseous
tissue transfer and/or osteofasciocutaneous free flap recon-
struction were considered.
2.1.4. Types of Outcome Measures
Primary Outcomes. Primary outcome measures of the review
included the success rate of free flap without any restric-
tions in follow-up. The other considered measures were the
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Table 1: Antiresorptive drugs used in oncologic and nononcologic patients. Btl: bottle; IM: intramuscular; IV: intravenous; MM: multiple
myeloma; PO: orally; SC: subcutaneous; SRE: skeletal-related event; Tab: tablet.
Pharmacologic
active ingredient Formulation
Route of
administration Indication and frequency
Alendronic acid
(sodium salt)
Tab 70 mg
Tab 10 mg PO
Treatment of postmenopausal osteoporosis (70
mg/week)
Treatment of osteoporosis in men (70 mg/week)
Treatment and prevention of osteoporosis induced by
glucocorticoids (70 mg/week)
Alendronic acid +
cholecalciferol Tab 70 mg/5600 UI PO
Treatment of postmenopausal osteoporosis in patients
with unsupplemented vitamin D deficit (70 mg/week)
Ibandronic acid
(monosodium salt
monohydrate)
Tab 50 mg
Btl 6 mg/6 ml
Tab 150 mg
Btl 3 mg/3 ml
PO
IV
PO
IV
Prevention of SREs in breast cancer patients with bone
metastases (50 mg/day p.o. or 6 mg every 3–4 weeks iv.)
Treatment of hypercalcemia of malignancy
Treatment of postmenopausal osteoporosis in patients
at high risk of fracture (150 mg/4 weeks p.o. or 3 mg
every 3 months iv.)
Neridronate acid
(sodium salt)
Btl 25 mg/2 ml
Btl 100 mg/8 ml
IV/IM.
IV
Osteogenesis imperfecta (2 mg/kg/3 months)
Paget’s bone disease (different schedules)
Pamidronic acid
(disodium salt)
Btl 15 mg/5 ml
Btl 30 mg/10 ml
Btl 60 mg/10 ml
Btl 90 mg/10 ml
IV
Prevention of SREs in breast cancer patients with bone
metastases or MM with bone lesions (60–90 mg every
3–4 weeks)
Treatment of hypercalcemia of malignancy
Zoledronic acid
(monohydrate)
Btl 4 mg/5 ml
Btl 5 mg/100 ml
IV
IV
Prevention of SREs in cancer patients with bone
metastases or MM (4 mg every 3–4 weeks).
Treatment of hypercalcemia of malignancy
Treatment of osteoporosis in postmenopausal women,
in men at increased risk of fracture, including those
with a recent hip fracture from minor trauma (5 mg
once per year)
Treatment of bone Paget’s disease
Denosumab Btl 120 mgBtl 60 mg
SC
SC
Prevention of SREs in cancer patients with bone
metastases (120 mg every 4 weeks)
Treatment of hypercalcemia of malignancy.
Osteoporosis (60 mg sc. every 6 months)
Table 2: Main antiangiogenic drugs used (IV: intravenous; MM: multiple myeloma; PO: orally; SC: subcutaneous; Btl: bottle; Tab: tablet).
Pharmacologic
active ingredient Formulation
Route of
administration Indication and frequency
Bevacizumab Btl 400 mgBtl 100 mg IV
Metastatic breast cancer (10 mg/kg every 2 weeks or 15
mg/kg every 3 weeks); colorectal cancer (5 mg/kg or 10
mg/kg every 2 weeks); lung/ovarian cancer (7.5 mg/kg
or 15 mg/kg every 3 weeks); renal cell cancer (10 mg/kg
every 2 weeks); glioblastoma (10 mg/kg every 2 weeks)
Sunitinib Tab 12.5 mg PO Renal cell cancer, GISTs and neuroendocrine tumors(50 mg/day for 4 weeks)
Sorafenib Tab 200 mg PO Renal cell cancer (800 mg/day)
Pazopanib Tab 200 mgTab 400 mg PO Renal cell cancer (200–800 mg/day)
Thalidomide Tab 50 mg PO Myeloma (400 mg/day for 6 weeks)
Lenalidomide Tab 5, 10, 15 and 25 mg PO Myeloma (tailored doses)
Everolimus Tab 5 and 10 mg PO Renal cell cancer, breast cancer (10 mg every day)
Temsirolimus Btl 30 mg IV Renal cell cancer (25 mg every week)
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Figure 1: Review process for the titles, abstracts, and full-text reading of the selected references.
Table 3: Drug-related risk factor of osteonecrosis of the jaw in the
cancer population according to Campisi et al. 2011 [11].
Risk Factor Strenght
Zoledronate vs Other Bisphosphonate +++
Intravenouse vs Oral Bisphosponate ++
Bisphosphonate cumulative dose +++
Bisphosphonate duration of treatment +++
Anti-angiogenic drugs ++
Denosumab ++
Chemotherapy -/+
Thalilomide +/-
frequency of MRONJ recurrence in the free flap or in the
surgical residual jaw bone.
Secondary Outcomes. The secondary measures of the review
entailed perioperative complications and those at follow-
up, including the most common cause of the MRONJ and
the time during which the patient was treated with the
antiresorptive or antiangiogenic drugs prior ONJ.
2.2. Data Extracted. Data extracted from the eighteen stud-
ies included number of patients, patient sex, and age,
predisposing factors for, and localisation of, MRONJ, type of
antiangiogenic or antiresorptive drugs and their cumulative
dose, clinical indications for the drug or combined therapy,
extent of the surgical excision, type of free vascularised tissue
reconstruction, free flap failure, immediate complications,
follow-up time, and MRONJ recurrence.
All selected papers were carefully read to identify
author(s), year of publication, study design, population and
treatment characteristics, and number of patients with recur-
rent MRONJ.
In case of missing information, we contacted the authors
and gave them 6 weeks to reply. If the information was still
missing we then indicated the missing data as “Not Reported
(NR)” in the text and in the tables.
3. Results
Results were expressed in descriptive statistics. No ran-
domised controlled clinical trials or case-controlled studies
comparing free flap reconstruction after resection inMRONJ
patients were found. A total number of 18 articles we included
in the study. All the published dates were described in case
report (no. 6) and case series (no. 12) from 2008 to 2017
(Table 6). A total of 83 patients, 47 females (56.62%), 19 males
(22.89%), and missing information for 20.49% (NR) of the
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Table 4: MRONJ staging according the AAOMS [7].
Stage MRONJ clinical findings
At risk category No apparent necrotic bone in patients who have been treated with either oral or IV bisphosphonates
Stage 0 No clinical evidence of necrotic bone, but non-specific clinical findings, radiographic changes and symptoms
Stage I Exposed and necrotic bone, or fistulae that probes to bone, in patients who are asymptomatic and have noevidence of infection
Stage II Exposed and necrotic bone, or fistulae that probes to bone, associated with infection as evidenced by pain anderythema in the region of the exposed bone with or without purulent drainage
Stage III
Exposed and necrotic bone or a fistula that probes to bone in patients with pain, infection, and one or more of
the following: exposed and necrotic bone extending beyond the region of alveolar bone, (i.e., inferior border
and ramus in the mandible, maxillary sinus and zygoma in the maxilla) resulting in pathologic fracture,
extra-oral fistula, oral antral/oral nasal communication, or osteolysis extending to the inferior border of the
mandible of sinus floor
Table 5: Systematic review currently published and their limitations.
Systematic Review Limitation
Sacco et al. (2011) [27] English literature limited search; Single Electronic database search.
Vercruysse et al. (2014) [25] Search Limited to BRONJ and or bisphosphonate related necrosis; No mentioning to language limitation;Review based on a single reviewer selection of articles
Neto et al. (2016) [26] Single Electronic database search; Search Limited to BRONJ and or bisphosphonate related necrosis; Nomentioning to language limitation; No mentioning reviewer involved in the search strategy.
Table 6: Study selected with total number of patient treated.
Study Type of study Patients number
Engroff and Kim (2007)
[28] Case series 2
Ferrari et al. (2008) [29] Case Report 1
Mu¨cke et al. (2009) [30] Case series 2
Nocini et al. (2009) [31] Case series 7
Seth et al. (2010) [32] Case series 11
Bedogni et al. (2011) [33] Case series 3
Pautke et al. (2011) [34] Case report 1
Bittner et al. (2012) [35] Case report 1
Ghazali et al. (2013) [36] Case report 1
Hanasono et al. (2013) [37] Case series 11
Horta et al. (2014) [38] Case series 1
Spinelli et al. (2014) [39] Case series 8
Vercruysse et al. (2014) [25] Case series 3
Kim et al. (2015) [40] Case series 4
Mu¨cke et al. (2016) [41] Case series 14
Neto et al. (2016) [26] Case report 1
Sotsuka et al. (2016) [42] Case report 1
Caldroney et al. (2017) [43] Case Series 11
cases, were treated using vascularised osseous tissue transfer
and/or osteofasciocutaneous free flap reconstruction.
The most common indications for antiresorptive or
antiangiogenic treatment were breast cancer (28.91%), mul-
tiple myeloma (22.89%), osteoporosis (14.45%), prostate can-
cer (9.63%), lung cancer (2.40%), myeloid-leukemia and
osteoporosis (1.20%), pain syndrome (1.20%), and NR in the
19.32% of the cases (Table 7). The most common site for
MRONJ was the mandible 97.59% and 2.41% in the maxilla
(Table 8).
Zoledronate was responsible for the majority of the
MRONJ with 42.16 %, then pamidronate 7.22%, alendronate
8.43%, ibandronate 2.40%, and etidronate 1.20%. A com-
bination of the following drugs and the relative incidence
percentage were also found responsible:
zoledronate and pamidronate (13.25%);
zoledronate and clodronate (1.20%);
zoledronate and denosumab (1.20%);
pamidronate and denosumab (1.20%);
alendronate, risedronate, and pamidronate (1.20%).
A total of 20.54% patients presented missing information
with regard to the type of drug used.
69.90% of the cases missed information on the causes of
the MRONJ.
Themost commonly utilised vascularised free flap recon-
struction was fibula free flap (81.92%), followed by iliac crest
(12.04%) and scapula (6.02%).
The most frequent type of resection was subtotal
(32.53%), followed by segmental (26.50%) and partial
(2.40%). However a large percentage of missing data was
found regarding the type of resection (NR 38.57%) (Table 9).
The patients were followed for a period of time ranging
from 2 weeks up to 99 months.
Radiographic imaging with CT, cone-beam, and/or
orthopantomogramwas obtained during follow-up in 95% of
the cases.
At follow-up and after free flap reconstruction, recur-
rence of MRONJ (6.02%) was observed in 5 patients: two
of the patients (2.40%) on the contralateral unresected part
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Table 7: Preoperative pharmacological analysis: type of drugs, indication for drug therapy, and time of drug exposure. ZOL: zoledronate;
ALD: alendronate; PMT: pamidronate; COL: clodronate; DZM: denosumab; IBA: ibandronate; ETI: etidronate; mth: months; RSD:
risedronate; NR: not reported.
Study Type of drug Indication for drug therapy time of drug exposure
Engroff and Kim (2007)
[28]
PMT (x 1 case)
ZOL (x 1 case) Brest Cancer (x 2 cases) NR
Ferrari et al. (2008) [29] PMT + ZOL Multiple Myeloma 21 mth (PMT)3 mth (ZOL) discontinue therapy
Mu¨cke et al. (2009) [30] ZOL (x 2 cases) Brest cancer (x 1 case);Multiple Myeloma (x 1 case)
50mth (ZOL)
36 mth (ZOL)
Nocini et al. (2009) [31] PMT and ZOL (x 5 cases)ZOL (x 2 cases)
Brest Cancer (x 5 cases);
Prostate Cancer (x 1 case);
Myeloid leukaemia and
Osteoporosis (x 1 case)
NR
Seth et al. (2010) [32]
ZOL (x 6 cases)
ALD (x 2 cases)
IBA (x 2 cases)
ETI (x 1 case)
Brest Cancer (x 5 cases);
Prostate Cancer (x 2 cases);
Multiple Myeloma (x 2 cases);
Osteoporosis (x 2 cases)
NR
Bedogni et al. (2011) [33] NR NR NR
Pautke et al. (2011) [34] ZOL Prostate Cancer 40 mth
Bittner et al. (2012) [35] ZOL and PMT Pain syndrome 12 mth (ZOL)3 mth (PMT)
Ghazali et al. (2013) [36] ALD Osteoporosis 84 mth (ALD)
Hanasono et al. (2013) [37] ZOL (x 9 cases)PMT (x 2 cases)
Multiple Myeloma (x 5 cases);
Breast Cancer (x 2 cases);
Prostate Cancer (x 2 cases);
Osteoporosis (x 2 cases)
NR
Horta et al. (2014) [38] ZOL Lung Cancer 36 mth (ZOL)
Spinelli et al. (2014) [39]
ZOL (x 3 cases)
PMT (x 3 cases)
ZOL and PMT (x 2 cases)
Multiple Myeloma (x 4 cases);
Brest Cancer (x 3 cases);
Prostate Cancer (x 1 case)
1 x 27 mth (ZOL)
1 x 21 mth (ZOL)
1 x 35 mth (ZOL
1 x 22 mth (PMT)
1 x 30 mth (PMT)
1 x 19 mth (PMT
1 x 25 mth (ZOL and PMT)
1 x 17 mth (ZOL and PMT)
Vercruysse et al. (2014) [25]
1 x ZOL
1 x ZOL + PMT
1 x ZOL + CLO
Multiple Myeloma (x 2 case);
Brest Cancer (x 1 case)
1 x 22mth (ZOL)
1x 12 mth (PMT) + 26 mth (ZOL)
1x 96 mth (CLO) + 29mth (ZOL)
Kim et al. (2015) [40]
ALD (x 2)
ALD + RSD + PMT (x 1)
ZOL + PMT (x 1)
Osteoporosis (x 3)
Multiple Myeloma (x 1)
1 x 48 mth (ALD)
1 x 120 mth (ALD
1 x 24 mth (ALD + RSD +PMT)
1 x 30mth (ZOL +PMT)
Mu¨cke et al. (2016) [41] NR NR NR
Neto et al. (2016) [26] ZOL Lung Cancer 36 mth (ZOL)
Sotsuka et al (2016) [42] ZOL Brest Cancer 59 mth (ZOL)
Caldroney et al. (2017) [43]
7 x ZOL
2 x ALD
1 x ZOL + DZM
1 x PMT + DZM
Brest Cancer (x 4 cases)
Osteoporosi (x 3 cases)
Multiple Myeloma (x 3 cases)
Prostate Cancer (x 1 case)
NR
of the jaw, other two patients (2.40%) on the margin of the
resection, and one patient (1.20%) on the grafted flap. The
overall free flap failure rate registered was 3.61% (Table 10).
3.1. Review Quality Assessment Data. All the studies and data
extraction included in the systematic review were qualitative
and the risk of bias assessed independently by the authors.
The authors used the CARE Checklist for case report and the
Modified Delphi Checklist for the case series studies.
In the six case report studies, we identified lack of clarity
in many of the thirteen domains, with missing information.
We found that the lack of clarity was predominantly on
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Table 8: Preoperative epidemiologic analysis (age, sex, predisposing factors, and site of the necrosis involved). M: male; F: female; NR: not
reported.
Study Type of study Patients number Age/Sex Trigging cause Site of the necrosisinvolved
Engroff and Kim (2007)
[28] Case series 2 64 (F); 49 (F)
Dental extraction
(x 2 cases)
Mandible (x 2
cases)
Ferrari et al. (2008) [29] Case report 1 66 (M) NR Mandible
Mu¨cke et al. (2009) [30] Case series 2 48 (F); 60 (F)
Dental Extraction
(x 1 case);
Spontaneous (x 1
case)
Mandible (x 2
cases)
Nocini et al. (2009) [31] Case series 7 NR (six F); (one M)
Oral surgery (x 5
cases);
Infection (x 2
cases)
Mandible (x 7
cases)
Seth et al. (2010) [32] Case series 11
68 (M); 56 (F); 50 (F); 72
(F); 48 (F); 71 (F); 67 (F); 60
(F); 51 (F); 72 (M); 60 (F)
NR Mandible (x 11cases)
Bedogni et al. (2011) [33] Case series 3 NR NR
Mandible (x 2
cases); Maxilla (x 1
case)
Pautke et al. (2011) [34] Case report 1 76 (M) Dental extraction Mandible
Bittner et al. (2012) [35] Case report 1 41 (F) Dental extraction Mandible
Ghazali et al. (2013) [36] Case report 1 82 (F) Dental extraction Mandible
Hanasono et al. (2013) [37] Case series 11
63 (F); 57 (M); 65 (M); 75
(F); 72 (M); 68 (M); 60 (F);
64 (F); 70 (F); 75 (F); 67 (F)
NR Mandible (x 11cases)
Horta et al. (2014) [38] Case series 1 54 M Spontaneous Mandible
Spinelli et al. (2014) [39] Case series 8
73 (M); 77 (F); 64 (F); 53
(F); 62 (M); 68 (F); 57 (M);
64 (F)
Dental extraction
(x 3 cases);
Spontaneous x 5
Mandible (x 8
cases)
Vercruysse et al. (2014) [25] Case series 3 54 (F); 70 (F); 64 (F)
Dental extraction
(x 1 case);
Spontaneous (x 2
cases)
Mandible (x 3
cases)
Kim et al. (2015) [40] Case series 4 69 (F), 68 (F), 62 (F), 70(M) NR Mandible (x 4)
Mu¨cke et al. (2016) [41] Case series 14 NR NR Mandible (x 14cases)
Neto et al. (2016) [26] Case report 1 58 (M) Spontaneous Mandible
Sotsuka et al. (2016) [42] Case report 1 50 (F) NR Maxilla
Caldroney et al. (2017) [43] Case series 11
56 (F); 65 (F); 60 (F); 61 (F);
65 (F); 64 (F); 68 (M); 67
(M); 73 (M); 72 (F); 73 (M).
NR Mandible (x 11cases)
follow-up and diagnostic procedure at the time of follow-up.
Hence we concluded the level of bias to be high for all the
included case report studies.
In the twelve case series studies, we reported a consistent
lack of clarity in some of the seven domains, predominantly
regarding the outcomemeasurement methods. Moreover, we
identified some missing information in few other domains;
hence we considered the level of bias to be high for all studies
We contacted the authors of these clinical cases to clarify
this bias; however we were unable to recover the missing
information.
4. Discussion
Some antiresorptive drugs such as BP or denosumab have
demonstrated to improve the quality of life in patients
affected by bone metastasis, osteoporosis, osteopenia, and
Paget disease. Additionally, a new antiangiogenic therapy
has been successfully used for specific cancer treatments.
However, this has remarkably increased the risk of developing
MRONJ. This risk is greater in patients who require a higher
administration dosage and an intake period greater than 2
years [14, 45, 46].
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Table 9: Operative analysis: type of surgery, type of free flap, flap failure, immediate postoperative complications (FFF: fibula Free flap; ICFF:
iliac crest free flap; SFF: scapula free flap).
Study Type of surgery Type of free flap Flap failure Immediate post-operativecomplications
Engroff and Kim (2007)
[28] 2 x Segmental 2 x FFF 0
Small Neck hematoma in
one patient
Ferrari et al. (2008) [29] Sub-total 1x FFF 0 0
Mu¨cke et al. (2009) [30] 2 x Segmental 1 x FFF; 1x ICFF 0 0
Nocini et al. (2009) [31] 7 x Subtotal 7 x FFF 0 Rupture of mini-plate inone patient
Seth et al. (2010) [32] NR 11 x FFF 0
Prolonged infection in one
patient; Fistula and
infection in three patients.
Bedogni et al. (2011) [33] NR 3 x FFF 1 (a year later) 0
Pautke et al. (2011) [34] Segmental 1 x ICFF 0 Fistula resolved withremoval of plate
Bittner et al. (2012) [35] Segmental 1 x SFF 0 0
Ghazali et al. (2013) [36] Segmental 1 x FFF 0 Sinus bradycardia
Hanasono et al. (2013) [37] 6 x subtotal5 x segmental 11 x FFF 1
Hematoma in one patient;
Pneumonia in one patient;
Deep vein thrombosis in
one patient; Small bowel
obstruction in one patient.
All complications occurred
in FFF
Horta et al. (2014) [38] 1 x segmental 1 x FFF 0 0
Spinelli et al. (2014) [39] 8 x subtotal 8 x FFF 0 0
Vercruysse et al. (2014) [25] 2 x Partial; 1 xSegmental 3 x ICFF
1 (segmental- 16 days
later) 1 (failure)
Kim et al. (2015) [40] NR 4 x FFF 0 0
Mu¨cke et al. (2016) [41] NR 9 x FFF5 x ICFF NR NR
Neto et al. (2016) [26] 1 x segmental 1 x FFF 0 0
Sotsuka et al. (2016) [42] NR 1 x FFF 0 0
Caldroney et al. (2017) [43] 6 x segmental5 x sub total
4 x SFF
7 x FFF 0
Two cases with wound
infection and dehiscence
and one case the plate was
removed. (3 different
patients). One FFF and two
SFF
Moreover, literature has reported that demography, cor-
ticosteroid therapy, systemic factors, and genetic factors
have been associated with MRONJ. A recent review report
showed a wide-ranging MRONJ incidence from 0 to 27.5%
in individuals exposed to intravenous BPs, with a mean
incidence of 7%, whereas it ranges from 0.1% to 0.06% in oral
administrations [47–49].
Etiopathogenesis of MRONJ is not yet fully understood.
Although no gold standard is currently available for the
treatment of jaw osteonecrosis, a number of studies debate
which MRONJ stage benefits the most from surgical therapy
[24, 50]. In general, for early stages of the disease (MRONJ
0 and I) conservative treatments might be sufficient; surgical
treatment should be restricted to advanced stages (MRONJ II
and III) or after failure of conservative treatments [7, 50].
The majority of researches as well as AAOMS consider
conservative treatments as the treatment of choice ofMRONJ.
However, there is not a robust evidence from clinical trials
as treatment recommendations mostly come from expert
opinions and are, therefore, characterised by a low level of
evidence [24, 47].
The authors of the 2009 AAOMS position statement rec-
ommend reserving resection and immediate reconstruction
to patients with stage III of the disease; however, positive
outcomes have been noted in patients with stages II and
III. Having said that no recommendations were given on
which type of reconstruction was to be considered the most
predictable [47]. The benefits of surgical management of
MRONJ have been extensively debated in literature and
radical surgery seems to offer more predictable and curative
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Table 10: Complications during follow-up time.
Study Follow-up time
Complications during
follow-up (included plate
removal)
MRONJ recurrence Site of recurrence
Engroff and Kim (2007)
[28] 2x12 months 0 Recurrence in one patient Contralateral
Ferrari et al. (2008) [29] 1 x 12 months Plate removal 0 0
Mu¨cke et al. (2009) [30] 2x 12 months 0 0 0
Nocini et al. (2009) [31]
1x 6 months
1 x 16 months
1 x 23 months
1 x 24 months
1 x 19 months
1 x 33 months
1 x 34 months
0 Recurrence in one patient Margin of the resection
Seth et al. (2010) [32]
1 x 10.0 months
1x 0.5 months
1x 30.8 months
1x 21.4 months
1x 17.8 months
1x 23.7 months
1x 10.6 months
1 x 14.2 months
1x 13.9 months
1x 12.2 months
1x 6.1 months
0 0 0
Bedogni et al. (2011) [33] NR failure of the FFF 1 yearlater 0 0
Pautke et al. (2011) [34] NR plate removal Recurrence in one patient On the free flap
Bittner et al. (2012) [35] NR 0 0 0
Ghazali et al. (2013) [36] 24 months 0 0 0
Hanasono et al. (2013) [37]
1 x 13.3 months
1x 20.1 months
1x 77.0 months
1x 23.8 months
1x 11.4 months
1 x 9.1 months
1x 9.1 months
1x 9.1 months
1x 8.1 months
2 x 3.0 months
0 0 0
Horta et al. (2014) [38] 1 x 12 months 0 0 0
Spinelli et al. (2014) [39]
1x 21.7 months
1x 25.1 months
1x 28.4 months
1x 32.2 months
1x 37 months
1x 28.4 months
1x 25.1 months
1x 32.9 months
0 0 0
Vercruysse et al. (2014) [25]
1x 36 months
1x 65 months
1x 76 months
Plate removal in one patient Recurrence in one patient Contralateral
Kim et al. (2015) [40]
1 x 99 months
1 x 18 months
1 x 12 months
1 x 7 months
Fracture of plate in one
patient 0 0
Mu¨cke et al. (2016) [41] 34.25 ± 33.3 months - Recurrence in one of thepatient Margin of the flap
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Table 10: Continued.
Study Follow-up time
Complications during
follow-up (included plate
removal)
MRONJ recurrence Site of recurrence
Neto et al. (2016) [26] 1 x 48 months 0 0 0
Sotsuka et al. (2016) [42] NR 0 0 0
Caldroney et al. (2017) [43]
3 x 6 months
2 x 44 months
1 x 69 months
1 x 36 months
1 x 28 months
1 x 10 months
1 x 17 months
1 x 11 months
Plate removal in one patient 0 0
results. However, surgical treatment of early stages ofMRONJ
remains controversial [47, 50–52].
Aggressive radical surgery is offered only to symptomatic
patients with extensive osteonecrosis, including those who
have previously failed conservative treatments [41].
This review has indicated that surgical therapy may
represent a treatment option for patients affected by MRONJ
stage III resulting in high success rates. Mucke et al. and
Caldroney et al. have documented excellent outcomes in
treating patient affected by MRONJ stage III in large cohort
studies [30, 43]. Since 2008 microvascular reconstruction of
the jaw has been documented as a viable option for MRONJ.
This systematic review confirmed that microsurgical recon-
struction therapy represents a feasible alternative in case of
treatment escalation.
Even though themajority of papers included in this study
were case reports and small case studies, the outcome of
free flap treatment has been promising with a significant low
recurrence of MRONJ and minimal surgical complications
[25, 26, 28–43].
The MRONJ recurrence rate found by this systematic
review was 6.02% (5 patients). The predominant recurrence
siteswere the contralateral unresected part of the jaw (2 cases)
and the margin of the resection (2 cases), both bearing an
overall recurrence rate of 2.40%. Just one case of recurrence
was found on the vascular reconstruction.
Infection was the most frequent complication found with
6.02% incidence.Theoverall free flap success ratewas 96.39%.
Three free flaps failed during a follow-up period ranging from
2 weeks up to 99 months.
Amongst all the types of reconstruction, free flap fibula
was the most chosen, followed by iliac crest and scapula with
success rates, respectively, of 97.60%, 98.80%, and 100%.
Antiresorptive drugs were explicitly discontinued in only
three studies out of the eighteen, while no mention was
reported in the remaining studies [31, 33, 41]. It is unclear
if the discontinuation strategy leads to a better surgical
outcome due to the long skeletal life of some antiresorptive
drugs.
In line with the growing body of literature, our findings
confirm positive results in treating patients with MRONJ
using free flaps microvascular reconstruction. In order to
obtain a possible resolution of MRONJ, patients with reason-
able life expectancy should be considered for microvascular
flap reconstruction after aggressive resection of the diseased
bone.
5. Conclusion
MRONJ is a significant adverse effect amongst patients
under antiresorptive agents. Although MRONJ pathogenesis
remains unclear, significant progress has been made with
respect to the diagnosis and staging of the disease, as well as
with risk-reduction strategies and treatments.This systematic
review based onmultiple-reviewer quality assessment criteria
was only able to select articles that meet Level 4 of the Oxford
Evidence-based medicine scale. Due to the nature of the
MRONJ incidence and the critical condition of the patients
affected by the primary disease, it is difficult to improve
the quality of evidence unless a common effort is applied.
Therefore, the authors believe that additional quality studies,
such as controlmulticentre studies or case-controlled studies,
are necessary to support the hypothesis of this study.
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